foxo4 dri peptide senolytic human trial Frontiers Development of a novel senolytic
Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $6.54 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



